Monopar Therapeutics Inc
MNPR40.370USD
-0.320-0.79%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
246.87MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Monopar Therapeutics Inc Unternehmen
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Unternehmensinformationen
BörsenkürzelMNPR
Name des UnternehmensMonopar Therapeutics Inc
IPO-datumDec 19, 2019
CEODr. Chandler D. Robinson, M.D.
Anzahl der mitarbeiter16
WertpapierartOrdinary Share
GeschäftsjahresendeDec 19
Addresse1000 Skokie Blvd Ste 350
StadtWILMETTE
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl60091-1146
Telefon18473880349
Websitehttps://www.monopartx.com/
BörsenkürzelMNPR
IPO-datumDec 19, 2019
CEODr. Chandler D. Robinson, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
73.47K
--
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Jul 5
Aktualisiert: Sat, Jul 5
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
Aktionäre
Aktionäre
Anteil
Janus Henderson Investors
18.55%
Tactic Pharma LLC
13.45%
Gem Pharmaceuticals LLC
9.99%
Adage Capital Management, L.P.
9.80%
RA Capital Management, LP
8.36%
Other
39.85%
Aktionärstypen
Aktionäre
Anteil
Corporation
29.77%
Investment Advisor/Hedge Fund
20.22%
Hedge Fund
16.45%
Venture Capital
8.36%
Individual Investor
4.79%
Investment Advisor
1.81%
Research Firm
0.55%
Pension Fund
0.15%
Other
17.91%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
75
5.02M
82.10%
-394.73K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
2023Q1
38
1.70M
67.19%
-3.29K
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Janus Henderson Investors
1.13M
18.55%
+87.51K
+8.36%
Mar 31, 2025
Tactic Pharma LLC
822.25K
13.45%
-33.33K
-3.90%
Apr 04, 2025
Gem Pharmaceuticals LLC
611.08K
9.99%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.8%
--
--
Mar 31, 2025
RA Capital Management, LP
511.21K
8.36%
--
--
Mar 31, 2025
AstraZeneca PLC
387.33K
6.33%
+387.33K
--
Oct 23, 2024
Point72 Asset Management, L.P.
168.16K
2.75%
+268.00
+0.16%
Mar 31, 2025
Adar1 Capital Management LLC
100.77K
1.65%
-29.26K
-22.50%
Mar 31, 2025
Hendricks (Diane)
93.75K
1.53%
--
--
Apr 04, 2025
Robinson (Chandler D)
73.47K
1.2%
+7.48K
+11.33%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
iShares Micro-Cap ETF
0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
ProShares UltraPro Russell2000
0.01%
ProShares Hedge Replication ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Anteil0.03%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.02%
ProShares UltraPro Russell2000
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%
Global X Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
iShares Russell 2000 ETF
Anteil0%
Avantis US Small Cap Equity ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Datum
Art
Verhältnis
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
Aug 09, 2024
Merger
5<1
